Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world single-arm study of flumatinib in newly diagnosed Ph+ chronic-phase CML
ChiCTR2000038179Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Very early molecular response. Started Oct 2020; status: recruiting.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2000038179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038179.